Abstracts tagged "Autoimmune diseases and diabetes"

Abstract Number: 2658 • 2013 ACR/ARHP Annual Meeting
Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes May Reduce The Risk Of Autoimmune Diseases
Seoyoung C. Kim¹, Sebastian Schneeweiss², Robert J. Glynn³, Michael Doherty³, Allison Goldfine⁴ and Daniel H. Solomon^5,6, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Joslin Diabetes Center, Boston, MA, ⁵Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Dipeptidyl peptidase-4 inhibitors (DPP4i), such as linagliptin, saxagliptin, and sitagliptin, are oral glucose-lowering drugs for type 2 diabetes mellitus (T2DM). DPP4 is a transmembrane…